98%
921
2 minutes
20
Alterations in the gut microbiota, known as gut dysbiosis, are associated with inflammatory bowel disease (IBD). There is a need for model systems that can recapitulate the IBD gut microbiome to better understand the mechanistic impact of differences in microbiota composition and its functional consequences in a controlled laboratory setting. To this end, we introduced fecal samples from patients with Crohn's disease (CD) and ulcerative colitis (UC), as well as from healthy control subjects, to miniature bioreactor arrays (MBRAs) and analyzed the microbial communities over time. We then performed two functional assessments. First, we evaluated the colitogenic potential of the CD microbiotas in genetically susceptible germ-free IL-10-deficient mice and found that colitogenic capacity was preserved in a bioreactor-cultivated CD microbiota. Second, we tested impaired colonization resistance against in UC microbiotas using the MBRA system and found that UC microbiotas were innately susceptible to colonization while healthy microbiotas were resistant, consistent with what is seen clinically. Overall, our results demonstrate that IBD microbiotas perform comparably to healthy donor microbiotas in the MBRA system, successfully recapitulating microbial structure while preserving IBD-specific functional characteristics. These findings establish a foundation for further mechanistic research into the IBD microbiota using MBRAs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12247916 | PMC |
http://dx.doi.org/10.1101/2025.05.09.653173 | DOI Listing |
ACS Biomater Sci Eng
August 2025
Center for Regenerative and Reconstructive Medicine, Med-X Institute, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Background: The engineering of large-scale tissues is frequently hampered by complex, inefficient perfusion bioreactors and the inherent diffusion limits of static culture. To overcome these operational and biological barriers, we developed and validated a novel, user-friendly dynamic culture platform.
Methods: Our miniaturized platform seamlessly integrates a peristaltic pump, an oxygenator, and perfusion circuits into a single, easy-to-assemble unit with smart control.
Alterations in the gut microbiota, known as gut dysbiosis, are associated with inflammatory bowel disease (IBD). There is a need for model systems that can recapitulate the IBD gut microbiome to better understand the mechanistic impact of differences in microbiota composition and its functional consequences in a controlled laboratory setting. To this end, we introduced fecal samples from patients with Crohn's disease (CD) and ulcerative colitis (UC), as well as from healthy control subjects, to miniature bioreactor arrays (MBRAs) and analyzed the microbial communities over time.
View Article and Find Full Text PDFBiotechnol J
July 2025
Centre for Soft Matter and Physics of Fluids, Bauman Moscow State Technical University, Moscow, Russia.
We review the recent advances in micro-scale bioreactors, analyzing their structural designs, limitations, and benefits for drug development, advanced biotechnology, and tissue engineering.
View Article and Find Full Text PDFBioprocess Biosyst Eng
June 2025
Institute of Bioprocess and Biosystems Engineering, Hamburg University of Technology, Denickestr. 15, 21073, Hamburg, Germany.
In large-scale bioprocesses, gradients in pH, dissolved oxygen level (DO), and substrate concentrations can decrease bioprocess efficiency. Scale-down bioreactors, be it single stirred-tank bioreactors with a special feeding regime, multi-compartment bioreactors, or combinations of bioreactors, offer a promising lab-scale solution for comprehending these gradients, as they allow adjustment of gradients without incurring high costs. However, critical challenges arise when transitioning from large-scale to scale-down bioreactors.
View Article and Find Full Text PDFMicroorganisms
April 2025
Biochemical Engineering, TUM School of Engineering and Design, Technical University of Munich, Boltzmannstraße 15, 85748 Garching, Germany.
A powerful strategy to accelerate bioprocess development is to complement parallel bioreactor systems with an automated approach, often achieved using liquid handling stations. The benefit of such high-throughput experiments is determined by the employed monitoring procedures. To gain a molecular understanding of the microbial production strains in miniaturized parallel single-use bioreactors, we extended the at-line monitoring procedures to transcriptome analysis in a parallel approach using RNA-Seq.
View Article and Find Full Text PDF